Visionary Asset Management Inc. cut its position in Eli Lilly and Co (NYSE:LLY) by 9.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,894 shares of the company’s stock after selling 3,869 shares during the period. Eli Lilly and accounts for about 0.9% of Visionary Asset Management Inc.’s investment portfolio, making the stock its 29th biggest position. Visionary Asset Management Inc.’s holdings in Eli Lilly and were worth $3,156,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Pathstone Family Office LLC lifted its position in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. acquired a new position in shares of Eli Lilly and during the second quarter worth approximately $494,000. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of Eli Lilly and during the second quarter worth approximately $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in shares of Eli Lilly and during the second quarter worth approximately $129,000. Hedge funds and other institutional investors own 76.30% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 251,088 shares of company stock valued at $22,041,236. 0.20% of the stock is currently owned by insiders.
Shares of Eli Lilly and Co (LLY) opened at $86.57 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market cap of $95,321.79, a P/E ratio of 21.17, a P/E/G ratio of 1.62 and a beta of 0.35. Eli Lilly and Co has a 12 month low of $74.00 and a 12 month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.88 earnings per share. analysts predict that Eli Lilly and Co will post 4.22 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.60%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is 98.58%.
A number of brokerages have recently issued reports on LLY. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Leerink Swann upped their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $92.14.
TRADEMARK VIOLATION NOTICE: This article was posted by Equities Focus and is the property of of Equities Focus. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.equitiesfocus.com/2018/01/07/eli-lilly-and-co-lly-holdings-reduced-by-visionary-asset-management-inc.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.